Aleida Verduguez-Orellana

Dr. Aleida Verduguez-Orellana

University of San Simón, Cochabamba, Bolivia
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2013 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JSJaime Soto
Jaime Soto
ERErnesto Rojas
Ernesto Rojas
MGMiguel Guzman
Miguel Guzman
AVAleida Verduguez-Orellana
Aleida Verduguez-Orellana
WNWinne Nena
Winne Nena
JBJonathan Berman
Jonathan Berman
Background. Cutaneous leishmaniasis is an ultimately self-curing disease for which systemic therapy with pentavalent antimony (Sb) is effective but with side effects. We evaluated 2 local treatments, intralesional (IL) Sb and cryotherapy, for single lesions due to Bolivian Leishmania (v.) braziliensis in a placebo-controlled study. Methods. Patients were randomized between IL Sb (650 µg/mm2 of lesion area on days 1, 3, and 5), cryotherapy (days 1 and 14), and placebo cream (daily for 20 days) in a 3:2:3 allocation. Lesion area was measured prior to therapy, and at 1, 3, and 6 months after therapy. The criteria for lesion cure were as follows: not doubling in size at 1 month, at least 50% diminution in size at 3 months, and complete reepithelialization at 6 months. Local adverse effects were recorded. Results. Cure rates were 21 of 30 (70%; 95% confidence interval [CI], 52%–83%) for IL Sb, 4 of 20 (20%; 95% CI, 8%–42%) for cryotherapy, and 5 of 30 (17%; 95% CI, 7%–34%) for placebo cream (P < .001 for IL Sb vs each other group). IL Sb adverse events were limited to injection site pain, with a mean value of 1.0 (mild). Conclusions. The comparative cure rate, small amount of drug administered, and tolerance data for IL Sb suggest that if local therapy for single L. braziliensis lesions is chosen, this treatment is attractive. Given the difficulties of performing placebo-controlled trials in the New World, the combined placebo and cryotherapy cure rate (18%; 95% CI, 10%–31%) is likely to become the standard against which future interventions for L. braziliensis are compared. Clinical Trials Registration. NCT01300975.

19 January 2014 in Food & Nutrition Research
Verified
Journal Article
Open access
PDF file
MGMiguel Guzman-Rivero
Miguel Guzman-Rivero
ERErnesto Rojas
Ernesto Rojas
AVAleida Verduguez-Orellana
Aleida Verduguez-Orellana
HPHenry Pardo
Henry Pardo
MTMary Cruz Torrico
Mary Cruz Torrico
ESEdgar Sejas
Edgar Sejas
Nutritional status in patients with cutaneous leishmaniasis and a study of the effects of zinc supplementation together with antimony treatment

Verified
Journal Article
Open access
PDF file
ECErnesto Rojas Cabrera
Ernesto Rojas Cabrera
AVAleida Verduguez-Orellana
Aleida Verduguez-Orellana
ITIgberto J. Tordoya-Titichoca
Igberto J. Tordoya-Titichoca
CSCcoya Sejas
Ccoya Sejas
RLRebeca Ledezma
Rebeca Ledezma
MGMiguel Guzman-Rivero
Miguel Guzman-Rivero
The standard of care for cutaneous leishmaniasis includes the intramuscular/intravenous administration of pentavalent antimonials that are toxic and poorly tolerated. Primary health care usually lacks trained health staff for the diagnosis and treatment of leishmaniasis in Cochabamba Bolivia. Taking these aspects into account, a Bolivian consortium set out to explore the intralesional administration of meglumine antimoniate to treat cutaneous leishmaniasis during primary care under programmatic conditions. A four-step strategy consisting of clinical training for intralesional treatment and the promotion and periodic follow-up of health staff was carried out. The training process was applied in situ to personnel of nine primary health care centres. The intralesional treatment was applied five times every other day. Clinical follow-up after six-months of treatment showed a 77% healing proportion and 5% of therapeutic failure among 152 enrolled patients. The drug volume used in the intralesional procedure was on average 1.7 mL/ulcer treated. In conclusion, the strategy used was successful and effective, accomplishing a healing proportion similar to the long standardized treatment with a reduced time of administration, no severe side effects, and it is feasible to conduct by trained health staff. Our study supports the current PAHO/WHO recommendation for the intralesional administration of pentavalent antimonials for the treatment of cutaneous leishmaniasis.

1 February 2015 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
MGMiguel Guzman-Rivero
Miguel Guzman-Rivero
AVAleida Verduguez-Orellana
Aleida Verduguez-Orellana
KMKaren Montaño
Karen Montaño
LCLieselotte Cloetens
Lieselotte Cloetens
ECErnesto Rojas Cabrera
Ernesto Rojas Cabrera
ESEdgar Sejas
Edgar Sejas

1 April 2014 in Biomedicine & Preventive Nutrition
Verified
Journal Article
Closed access
MGMiguel Guzman-Rivero
Miguel Guzman-Rivero
AVAleida Verduguez-Orellana
Aleida Verduguez-Orellana
MCMarisol Cordova
Marisol Cordova
LMLuis Maldonado
Luis Maldonado
MMMarcos Medina
Marcos Medina
BÅBjörn Åkesson
Björn Åkesson

30 June 2022 in Gaceta Médica Boliviana
Verified
Journal Article
Open access
Jhonny Limachi-ChoqueJhonny Limachi-Choque
Jhonny Limachi-Choque
AVAleida Verduguez-Orellana
Aleida Verduguez-Orellana